Psoriasis drug, Ixekizumab, very effective in Phase III trials

About 80 percent of patients with moderate to severe psoriasis saw their disease completely or almost completely cleared with a new drug called ixekizumab, according to three large, long-term clinical trials led by Northwestern Medicine. The results of these phase III trials were compiled in a paper published in the New England Journal of Medicine. ["]